ATXN2 Antibodies

ATXN2 antibodies are designed to specifically target Ataxin-2 (ATXN2), a protein implicated in cellular processes such as RNA metabolism, stress response, and signal transduction. Mutations and abnormal expansions in the ATXN2 gene are associated with spinocerebellar ataxia type 2 (SCA2), a neurodegenerative disorder characterized by progressive loss of motor coordination, as well as increased risk for amyotrophic lateral sclerosis (ALS). 

Content

Ataxin-2 (ATXN2) is a multifunctional protein involved in various cellular processes, including the regulation of RNA translation, endocytosis, and stress granule formation. It interacts with RNA-binding proteins and plays a critical role in maintaining RNA homeostasis. Pathologically, expanded polyglutamine (polyQ) repeats in ATXN2 lead to the formation of toxic protein aggregates, which disrupt normal cellular function and contribute to neurodegenerative processes, such as those observed in SCA2 and ALS. 

Application

ATXN2 antibodies are widely used in several research applications, including:

• Western Blotting (WB): For the detection and quantification of Ataxin-2 protein in cell and tissue samples. This technique helps in assessing protein levels, identifying mutant forms, and analyzing post-translational modifications that may influence ATXN2 function.
• Immunohistochemistry (IHC): Used to visualize the localization and distribution of ATXN2 in tissue sections, particularly in the brain and spinal cord. IHC with ATXN2 antibodies is crucial for identifying regions affected by ATXN2 aggregation, especially in SCA2 and ALS patients.
• Immunoprecipitation (IP): Applied to isolate ATXN2 from complex protein mixtures, enabling the study of its protein-protein interactions, aggregation properties, and functional characteristics in normal and disease states.

These applications make ATXN2 antibodies essential tools for investigating the role of Ataxin-2 in neurodegenerative diseases.  They contribute to understanding the molecular mechanisms driving conditions like SCA2 and ALS, providing a foundation for the development of targeted therapeutic strategies aimed at modulating ATXN2 function and preventing pathological aggregation.